In MM, several surface molecules or molecular pathways are druggable and targeted, including CD38, CD56, SLAMF7, CD138, programmed cell death-ligand 1(PD-L1), and BCMA [19,37,38,39]. This evidence concerns the gene CD274 and Miyoshi myopathy.